CY1110813T1 - Χημικες ενωσεις - Google Patents
Χημικες ενωσειςInfo
- Publication number
- CY1110813T1 CY1110813T1 CY20101100879T CY101100879T CY1110813T1 CY 1110813 T1 CY1110813 T1 CY 1110813T1 CY 20101100879 T CY20101100879 T CY 20101100879T CY 101100879 T CY101100879 T CY 101100879T CY 1110813 T1 CY1110813 T1 CY 1110813T1
- Authority
- CY
- Cyprus
- Prior art keywords
- chemical compounds
- compounds
- 11βhsd1
- inhibition
- processes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86424706P | 2006-11-03 | 2006-11-03 | |
| US86430306P | 2006-11-03 | 2006-11-03 | |
| EP07824375A EP2086939B8 (en) | 2006-11-03 | 2007-10-31 | Pyridine carboxamides as 11-beta-hsd1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110813T1 true CY1110813T1 (el) | 2015-06-10 |
Family
ID=39304797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100879T CY1110813T1 (el) | 2006-11-03 | 2010-10-04 | Χημικες ενωσεις |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US7964618B2 (enExample) |
| EP (2) | EP2086939B8 (enExample) |
| JP (1) | JP5165688B2 (enExample) |
| KR (1) | KR101465275B1 (enExample) |
| CN (3) | CN101573336B (enExample) |
| AR (1) | AR063458A1 (enExample) |
| AT (1) | ATE475649T1 (enExample) |
| AU (1) | AU2007315955B2 (enExample) |
| BR (1) | BRPI0717970C1 (enExample) |
| CA (1) | CA2668006C (enExample) |
| CL (1) | CL2007003176A1 (enExample) |
| CO (1) | CO6321130A2 (enExample) |
| CY (1) | CY1110813T1 (enExample) |
| DE (1) | DE602007008137D1 (enExample) |
| DK (1) | DK2086939T3 (enExample) |
| ES (2) | ES2347491T3 (enExample) |
| HR (1) | HRP20100522T1 (enExample) |
| IL (1) | IL198231A0 (enExample) |
| MX (1) | MX2009004707A (enExample) |
| NO (1) | NO20091603L (enExample) |
| NZ (1) | NZ576501A (enExample) |
| PE (1) | PE20081487A1 (enExample) |
| PL (1) | PL2086939T3 (enExample) |
| PT (1) | PT2086939E (enExample) |
| RS (1) | RS51451B (enExample) |
| RU (1) | RU2451674C2 (enExample) |
| SI (1) | SI2086939T1 (enExample) |
| TW (1) | TW200827346A (enExample) |
| UY (1) | UY30681A1 (enExample) |
| WO (1) | WO2008053194A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101024227B1 (ko) | 2005-11-21 | 2011-03-29 | 시오노기세이야쿠가부시키가이샤 | 11-β-히드록시스테로이드 탈수소효소 제 Ⅰ 형에 대한저해 활성을 갖는 헤테로시클릭 화합물 |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| TW200836719A (en) * | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| CN103288738B (zh) | 2007-05-18 | 2016-03-16 | 盐野义制药株式会社 | 具有11β-羟基类固醇脱氢酶I型抑制活性的含氮杂环衍生物 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5441705B2 (ja) | 2007-10-15 | 2014-03-12 | 武田薬品工業株式会社 | アミド化合物およびその用途 |
| WO2009056881A1 (en) * | 2007-10-29 | 2009-05-07 | Astrazeneca Ab | Chemical compounds 313 |
| MX2010008583A (es) * | 2008-02-04 | 2010-08-30 | Astrazeneca Ab | Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico. |
| AU2009239794A1 (en) * | 2008-04-22 | 2009-10-29 | Astrazeneca Ab | Substituted pyrimidin-5-carboxamides 281 |
| EP2243479A3 (en) | 2009-04-20 | 2011-01-19 | Abbott Laboratories | Novel amide and amidine derivates and uses thereof |
| CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
| US20110092526A1 (en) * | 2009-10-20 | 2011-04-21 | Astrazeneca Ab | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 |
| IN2012DN05125A (enExample) * | 2009-11-24 | 2015-10-23 | Allergan Inc | |
| US8871208B2 (en) * | 2009-12-04 | 2014-10-28 | Abbvie Inc. | 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR20110123657A (ko) * | 2010-05-07 | 2011-11-15 | 에스케이케미칼주식회사 | 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| CA2809675A1 (en) | 2010-09-23 | 2012-03-29 | Shuang Chen | Monohydrate of an azaadamantane derivative |
| US8471027B2 (en) * | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
| EP2735567B1 (en) * | 2011-07-21 | 2016-10-26 | Xuanzhu Pharma Co., Ltd. | Heterocyclic substituted pyrimidine compound |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN102659657B (zh) * | 2012-04-24 | 2014-08-06 | 徐州医学院 | 一种蛋白酶抑制剂pf429242的合成方法 |
| AU2013279510A1 (en) | 2012-06-20 | 2014-10-16 | F. Hoffmann-La Roche Ag | Substituted pyrazole compounds as LPAR antagonists |
| EP2864300A1 (en) | 2012-06-20 | 2015-04-29 | F. Hoffmann-La Roche AG | N-alkyltriazole compounds as lpar antagonists |
| EP3821892A1 (en) | 2019-11-12 | 2021-05-19 | University of Leeds | (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds |
| GB202216324D0 (en) * | 2022-11-02 | 2022-12-14 | Cerevance Ltd | Novel compounds |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR66581B (enExample) | 1978-02-21 | 1981-03-27 | Delalande Sa | |
| US4734418A (en) | 1984-12-14 | 1988-03-29 | Mitsui Petrochemical Industries, Ltd. | Quinazoline compounds and antihypertensives |
| IL148291A0 (en) | 1999-09-16 | 2002-09-12 | Tanabe Seiyaku Co | Aromatic nitrogen-containing 6-membered cyclic compounds |
| FR2803592A1 (fr) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant. |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| US6777446B2 (en) | 2000-09-05 | 2004-08-17 | Tularik, Inc. | FXR modulators |
| NZ526003A (en) | 2000-10-20 | 2005-09-30 | Biocryst Pharm Inc | Biaryl compounds as serine protease inhibitors |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1492541A1 (en) | 2002-04-05 | 2005-01-05 | The University Of Edinburgh | Pharmaceutical compositions comprising a 11-beta hydroxysteroid dehydrogenase inhibitor and a diuretic agent |
| WO2004039795A2 (en) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
| TW200503994A (en) * | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| SE0300457D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| SE0300458D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| EP1600442B1 (en) | 2003-02-26 | 2018-01-17 | Msd K.K. | Heteroarylcarbamoylbenzene derivative |
| JP4629657B2 (ja) | 2003-04-11 | 2011-02-09 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物 |
| WO2005016877A2 (en) | 2003-08-07 | 2005-02-24 | Merck & Co., Inc. | Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| CN102060806A (zh) | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
| GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| KR20060101772A (ko) | 2003-12-19 | 2006-09-26 | 화이자 인코포레이티드 | 당뇨병 및 비만을 치료하기 위한,11-베타-하이드록시스테로이드 데하이드로게나제 유형1(11-베타-ｈｓｄ-1)의 저해제로서의벤젠설폰일아미노-피리딘-2-일 유도체 및 관련 화합물 |
| JP2007523206A (ja) | 2004-02-24 | 2007-08-16 | グラクソ グループ リミテッド | Ｃｂ２受容体モジュレーターとしてのピリジン誘導体およびその使用 |
| CN1972914A (zh) * | 2004-03-31 | 2007-05-30 | 詹森药业有限公司 | 作为组胺h3受体配合体的非咪唑杂环化合物 |
| JP2007536369A (ja) | 2004-05-06 | 2007-12-13 | ファイザー・インク | プロリン及びモルホリン誘導体の新規化合物 |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| DK1763517T3 (da) | 2004-06-28 | 2011-06-06 | Hoffmann La Roche | Pyrimidinderivater som 11beta-HSD1-inhibitorer |
| CA2585735A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Novel compounds of substituted and unsubstituted adamantyl amides |
| JP2008519034A (ja) | 2004-11-03 | 2008-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネル調節剤としてのピリミジン誘導体および使用方法 |
| KR101496206B1 (ko) | 2005-01-05 | 2015-02-27 | 애브비 인코포레이티드 | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체 |
| WO2006106052A1 (en) | 2005-04-05 | 2006-10-12 | F. Hoffmann-La Roche Ag | Pyrazoles |
| CN101155781B (zh) | 2005-04-06 | 2012-11-07 | 霍夫曼-拉罗奇有限公司 | 作为cb1逆激动剂的吡啶-3-甲酰胺衍生物 |
| WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| EP2527337A1 (en) | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| WO2006125958A1 (en) | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | 2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators |
| TW200716576A (en) | 2005-06-07 | 2007-05-01 | Shionogi & Co | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| KR100970294B1 (ko) | 2005-06-08 | 2010-07-15 | 니뽄 다바코 산교 가부시키가이샤 | 복소환 화합물 |
| DE602006010546D1 (de) | 2005-06-16 | 2009-12-31 | Pfizer | N-(pyridin-2-yl)sulfonamidderivate |
| NZ564608A (en) | 2005-07-09 | 2009-09-25 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| US20100160286A1 (en) | 2005-08-09 | 2010-06-24 | Astrazeneca Uk Limited Ab | Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes |
| CA2627813A1 (en) | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted pyrrolones as allosteric modulators of glucokinase |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| KR101024227B1 (ko) | 2005-11-21 | 2011-03-29 | 시오노기세이야쿠가부시키가이샤 | 11-β-히드록시스테로이드 탈수소효소 제 Ⅰ 형에 대한저해 활성을 갖는 헤테로시클릭 화합물 |
| BRPI0707408A2 (pt) | 2006-01-31 | 2011-05-03 | Incyte Corp | compostos de amido e seu uso como produtos farmacêuticos |
| WO2007107470A2 (en) | 2006-03-22 | 2007-09-27 | F. Hoffmann-La Roche Ag | Pyrazoles as 11-beta-hsd-1 |
| EP2010479A1 (en) | 2006-04-07 | 2009-01-07 | High Point Pharmaceuticals, LLC | 11 beta-hydroxysteroid dehydrogenase type 1 active compounds |
| MX2008013285A (es) | 2006-04-27 | 2008-10-24 | Solvay Pharm Gmbh | Uso novedoso de moduladores del receptor canabinoide cbx como moduladores de los canales de potasio. |
| WO2008012532A2 (en) | 2006-07-27 | 2008-01-31 | Astrazeneca Ab | : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase |
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| TW200836719A (en) | 2007-02-12 | 2008-09-16 | Astrazeneca Ab | Chemical compounds |
| CN103288738B (zh) | 2007-05-18 | 2016-03-16 | 盐野义制药株式会社 | 具有11β-羟基类固醇脱氢酶I型抑制活性的含氮杂环衍生物 |
| AU2008277783B2 (en) | 2007-07-17 | 2012-09-20 | F. Hoffmann-La Roche Ag | Inhibitors of 11beta-hydroxysteroid dehydrogenase |
| US20110060022A1 (en) | 2007-11-06 | 2011-03-10 | Astrazeneca Ab | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic Acid - 465 |
| MX2010008583A (es) | 2008-02-04 | 2010-08-30 | Astrazeneca Ab | Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico. |
| AU2009239794A1 (en) | 2008-04-22 | 2009-10-29 | Astrazeneca Ab | Substituted pyrimidin-5-carboxamides 281 |
| CN102300851A (zh) | 2009-01-30 | 2011-12-28 | 阿斯利康(瑞典)有限公司 | 制备含羧基的吡唑酰氨基化合物597的新方法 |
| US20110092526A1 (en) | 2009-10-20 | 2011-04-21 | Astrazeneca Ab | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 |
-
2007
- 2007-10-29 TW TW096140633A patent/TW200827346A/zh unknown
- 2007-10-30 US US11/928,744 patent/US7964618B2/en active Active
- 2007-10-31 DE DE602007008137T patent/DE602007008137D1/de active Active
- 2007-10-31 BR BRPI0717970A patent/BRPI0717970C1/pt active IP Right Grant
- 2007-10-31 CN CN2007800491675A patent/CN101573336B/zh not_active Expired - Fee Related
- 2007-10-31 AT AT07824375T patent/ATE475649T1/de active
- 2007-10-31 EP EP07824375A patent/EP2086939B8/en active Active
- 2007-10-31 CN CN2010101438299A patent/CN101787016B/zh active Active
- 2007-10-31 CA CA2668006A patent/CA2668006C/en active Active
- 2007-10-31 KR KR1020097010339A patent/KR101465275B1/ko active Active
- 2007-10-31 SI SI200730335T patent/SI2086939T1/sl unknown
- 2007-10-31 RS RSP-2010/0422A patent/RS51451B/sr unknown
- 2007-10-31 AU AU2007315955A patent/AU2007315955B2/en active Active
- 2007-10-31 WO PCT/GB2007/004131 patent/WO2008053194A2/en not_active Ceased
- 2007-10-31 RU RU2009115830/04A patent/RU2451674C2/ru active
- 2007-10-31 ES ES07824375T patent/ES2347491T3/es active Active
- 2007-10-31 DK DK07824375.5T patent/DK2086939T3/da active
- 2007-10-31 CN CN2012100119350A patent/CN102603711A/zh active Pending
- 2007-10-31 NZ NZ576501A patent/NZ576501A/en not_active IP Right Cessation
- 2007-10-31 PT PT07824375T patent/PT2086939E/pt unknown
- 2007-10-31 UY UY30681A patent/UY30681A1/es not_active Application Discontinuation
- 2007-10-31 HR HR20100522T patent/HRP20100522T1/hr unknown
- 2007-10-31 JP JP2009535119A patent/JP5165688B2/ja active Active
- 2007-10-31 EP EP10163730.4A patent/EP2233480B1/en active Active
- 2007-10-31 PL PL07824375T patent/PL2086939T3/pl unknown
- 2007-10-31 MX MX2009004707A patent/MX2009004707A/es active IP Right Grant
- 2007-10-31 ES ES10163730T patent/ES2423206T3/es active Active
- 2007-11-02 AR ARP070104887A patent/AR063458A1/es not_active Application Discontinuation
- 2007-11-02 CL CL200703176A patent/CL2007003176A1/es unknown
- 2007-11-05 PE PE2007001517A patent/PE20081487A1/es not_active Application Discontinuation
-
2009
- 2009-04-20 IL IL198231A patent/IL198231A0/en unknown
- 2009-04-22 NO NO20091603A patent/NO20091603L/no not_active Application Discontinuation
- 2009-04-29 CO CO09043382A patent/CO6321130A2/es not_active Application Discontinuation
- 2009-08-14 US US12/541,565 patent/US8673938B2/en active Active
- 2009-08-14 US US12/541,574 patent/US20090312372A1/en not_active Abandoned
-
2010
- 2010-10-04 CY CY20101100879T patent/CY1110813T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110813T1 (el) | Χημικες ενωσεις | |
| NO20073790L (no) | Kjemiske forbindelser | |
| NO20073788L (no) | Kjemiske forbindelser | |
| SE0301700D0 (sv) | Novel compounds | |
| EA201001205A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
| TW200800999A (en) | Novel compounds | |
| SE0302811D0 (sv) | Novel compounds | |
| UY30759A1 (es) | Compuestos quimicos | |
| TW200716606A (en) | Chemical compounds | |
| TW200800963A (en) | Chemical compounds | |
| UY31145A1 (es) | Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene | |
| TW200801003A (en) | Novel compounds | |
| TW200745084A (en) | Novel compounds | |
| BRPI0815920A2 (pt) | Composto, composição farmacêutica, e, uso do composto. | |
| MY153915A (en) | Organic compounds | |
| UA103319C2 (en) | Thiazole- and oxazole-benzene sulfonamide compounds | |
| CY1111454T1 (el) | Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων | |
| SE0401762D0 (sv) | Novel compounds | |
| UY30544A1 (es) | Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones | |
| CY1112960T1 (el) | Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων | |
| TW200738627A (en) | Trialkylsilyl-indoles | |
| CY1116000T1 (el) | Υποκατεστημενες πυραζολες, συνθεσεις που τις περιεχουν, μεθοδος παραγωγης και χρηση | |
| TW200738659A (en) | Novel compounds | |
| SE0303541D0 (sv) | New compounds | |
| SE0303280D0 (sv) | Novel compounds |